ChronoScale Q1 revenue $41.5M, up 148% YoY; net loss widens to $26.4M

EKSO BIONICS HOLDINGS, INC.

2027-Q1 EPS reported -$0.29 vs consensus -$0.09 ▼ miss (-215.9%)

Revenue $41.5M vs $16.7M a year ago (+148%), driven by AI infrastructure hardware resale to a new customer; cost of revenues $45.6M, up 91% YoY.
Net loss from continuing operations $26.4M ($0.18 basic/diluted) vs $11.2M ($0.08) prior year; Adjusted EBITDA $5.9M vs $9.4M.
Secured 50 MW AI compute deployment with Microsoft in North America using NVIDIA GB300 NVL72 systems; also Nutanix partnership and 3-year Baseten Labs deal (~4 MW, completion calendar Q1 2027).
Sold Legacy Ekso Business on Sept 30, 2026; discontinued-operations net loss $16.1M; cash and equivalents $15.2M as of Aug 31, 2026.
Received $328.2M in aggregate customer prepayments; contract extension plus new customer agreement puts company on track for $1B annualized run-rate revenue by calendar Q3 2027.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.